Sumit Aggarwal - 10 Jun 2026 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc. (ELOX)

Reporting relationship: President and CEO, Director
Issuer ticker: ELOX
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2026, 20:00:54 UTC
Prior SEC filing: 28 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Sumit Aggarwal

Key filing fact

Sumit Aggarwal filed Form 4 for Eloxx Pharmaceuticals, Inc. (ELOX) on 10 Jun 2026.

Key facts

This page summarizes Sumit Aggarwal's Form 4 filing for Eloxx Pharmaceuticals, Inc. (ELOX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2026, 20:00.

Change

Previous filing in this sequence was filed on 28 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001854362 Primary reporting owner

Aggarwal Sumit

Relationship: President and CEO, Director
Address: C/O ELOXX PHARMACEUTICALS, INC., P.O. BOX 274, ARLINGTON
Signature: /s/ Sumit Aggarwal
Signature date: 10 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELOX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +328,833
Change %
Price: $0.000000^*
Shares after: 328,833
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 328,833
Exercise price: $1.65
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted on September 19, 2025 and was subject to a performance-based vesting condition that was satisfied on June 10, 2026. The option will vest as to 1/36 on July 31, 2026, with the remaining options vesting in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuing service on each such vesting date.